Search Results for "Metabolic"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Metabolic. Results 91 to 100 of 1047 total matches.

Comparison Table: Some Oral Antiseizure Medications (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
of multiple hepatic enzymes; can reduce levels of drugs metabolized by these enzymes CYP3A4 inhibitors ...
View the Comparison Table: Some Oral Antiseizure Medications
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e133-40   doi:10.58347/tml.2024.1708b |  Show IntroductionHide Introduction

Turmeric Supplements

   
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019  (Issue 1585)
transporter P-glycoprotein (P-gp); it could increase serum concentrations of drugs that are metabolized ...
Turmeric is a spice derived from the Curcuma longa plant. Dietary supplements and foods containing turmeric are widely promoted for relief of pain and to improve joint mobility, immunity, digestion, cardiovascular health, depression, anxiety, memory, and cognition.
Med Lett Drugs Ther. 2019 Nov 18;61(1585):185 |  Show IntroductionHide Introduction

Pharmacogenetic-Based Dosing of Warfarin

   
The Medical Letter on Drugs and Therapeutics • May 19, 2008  (Issue 1286)
) that affect coumarin metabolism and sensitivity may help clinicians estimate the therapeutic warfarin dose ...
Warfarin sodium (Coumadin, and others) and other coumarin anticoagulants prevent thrombosis, but patient response is highly variable and overanticoagulation can lead to hemorrhage. Genotyping patients for single nucleotide polymorphisms (SNPs) that affect coumarin metabolism and sensitivity may help clinicians estimate the therapeutic warfarin dose. The FDA has added a note to warfarin labeling recommending lowrange doses for patients with such genetic variations. Commercial tests for these variants are now available and cost about $500 per test.
Med Lett Drugs Ther. 2008 May 19;50(1286):39-40 |  Show IntroductionHide Introduction

Tetrabenazine (Xenazine) for Huntington's Chorea

   
The Medical Letter on Drugs and Therapeutics • Jan 26, 2009  (Issue 1304)
Oral Formulation 12.5 and 25 mg tablets Metabolism Hepatic by CYP2D6 Elimination Renal Half-life ...
Tetrabenazine (Xenazine - Ovation Pharmaceuticals), an old drug first synthesized 50 years ago for treatment of schizophrenia, was recently approved by the FDA for the treatment of chorea associated with Huntington's disease. It has been available in other countries for decades.
Med Lett Drugs Ther. 2009 Jan 26;51(1304):7-8 |  Show IntroductionHide Introduction

Lesinurad (Zurampic) for Gout-Associated Hyperuricemia

   
The Medical Letter on Drugs and Therapeutics • Nov 21, 2016  (Issue 1508)
200 mg tablets Tmax 1-4 hours Metabolism Hepatic, mainly by CYP2C9 Elimination Urine (63%); feces ...
The FDA has approved lesinurad (Zurampic – Ironwood), a uric acid transporter 1 (URAT1) inhibitor, for adjunctive treatment of gout-associated hyperuricemia in patients whose serum uric acid levels fail to reach goal with xanthine oxidase inhibitor monotherapy.
Med Lett Drugs Ther. 2016 Nov 21;58(1508):148-50 |  Show IntroductionHide Introduction

Drugs for Anxiety Disorders

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023  (Issue 1682)
third-line treatment; they can cause weight gain, metabolic adverse effects, akathisia, and tardive ...
Anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder, and various phobias) are the most common form of psychiatric illness. They can be treated effectively with cognitive behavioral therapy (CBT) and/or pharmacotherapy.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):121-8   doi:10.58347/tml.2023.1682a |  Show IntroductionHide Introduction

Nefazodone for Depression

   
The Medical Letter on Drugs and Therapeutics • Apr 14, 1995  (Issue 946)
undergoes extensive first-pass metabolism in the liver, resulting in three active metabolites, one of which ...
Nefazodone (Serzone - Bristol-Myers Squibb) was recently approved by the US Food and Drug Administration for treatment of depression. A phenylpiperazine, nefazodone is chemically related to trazodone (Desyrel, and others).
Med Lett Drugs Ther. 1995 Apr 14;37(946):33-5 |  Show IntroductionHide Introduction

Lopinavir/Ritonavir: A Protease-inhibitor Combination

   
The Medical Letter on Drugs and Therapeutics • Jan 08, 2001  (Issue 1095)
of a pharmacokinetic interaction between the drugs. Lopinavir is metabolized by hepatic P450 CYP3A. Ritonavir ...
Lopinavir/ritonavir is the first fixed-dose combination of protease inhibitors approved by the FDA for the treatment of HIV infection. It is being marketed for use with other drugs in adults and children more than six months old. Lopinavir is a new drug available only in this combination. Ritonavir is often used with other protease inhibitors to raise their plasma concentrations.
Med Lett Drugs Ther. 2001 Jan 8;43(1095):1-2 |  Show IntroductionHide Introduction

Chromium Supplementation

   
The Medical Letter on Drugs and Therapeutics • Jan 16, 2006  (Issue 1226)
9 or has beneficial effects on glucose metabolism in subjects who do not have type 2 diabetes. 10 ...
Chromium is marketed as a dietary supplement, usually containing 20-500 mcg of a chromium salt. It has been promoted for weight loss, muscle building, and for prevention and treatment of diabetes, among other claims. As a dietary supplement, chromium can be sold without proof of efficacy or safety.
Med Lett Drugs Ther. 2006 Jan 16;48(1226):7-8 |  Show IntroductionHide Introduction

Ticagrelor (Brilinta) - Better than Clopidogrel (Plavix)?

   
The Medical Letter on Drugs and Therapeutics • Sep 05, 2011  (Issue 1372)
(ticagrelor); 2.5 hours (active metabolite) Metabolism Hepatic by CYP2C19 Hepatic by CYP3A4 and 2B6 Hepatic ...
The FDA has approved ticagrelor (Brilinta – AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. Clopidogrel is expected to become available generically in the US within the next few months.
Med Lett Drugs Ther. 2011 Sep 5;53(1372):69-70 |  Show IntroductionHide Introduction